Adamas Pharmaceuticals Long Term Debt

As of the most recent data (September 2021), ADMS shows a long-term debt of $120M. That compares with $130M in the prior-year period — down 1.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ADMS's long-term debt is now $120M (was $130M) — a 1.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Adamas Pharmaceuticals is outperforming or lagging.

Tracking ADMS's long-term debt over time shows whether Adamas Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $120M That compares with $130M in the prior-year period — down 1.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Adamas Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $120M) with ownership activity and broader fundamentals.

Adamas Pharmaceuticals's long-term debt is $120M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.